Results 51 to 60 of about 32,416 (217)

New Vaccines for the Prevention of Pneumococcal Infections

Emerging Infectious Diseases, 1996
Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections
Helena Käyhty, Juhani Eskola
doaj   +1 more source

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

JEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz, Lars Matthies, Andrea Vanegas Ramirez   +2 more
wiley   +1 more source

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. [PDF]

, 2012
OBJECTIVE: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.
Edmunds, W. John, van Hoek, Albert Jan, Trotter, Caroline L, Rozenbaum, Mark H., C. L. Trotter, Miller, Elizabeth, Rozenbaum, Mark H, D. Fleming, Trotter, Caroline L., E. Miller, M. H. Rozenbaum, Edmunds, W John, W. J. Edmunds, Fleming, Douglas, A. J. van Hoek   +14 more
core   +1 more source

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Infectious Diseases and Therapy
Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years ...
Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood   +11 more
doaj   +1 more source

Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme

Acta Paediatrica, EarlyView.
ABSTRACT Aim Under Swedish law, a vaccination may be included in the National Immunisation Programme (NIP) if it effectively prevents transmission in the population, is cost‐effective and aligns with ethical and humanitarian principles. The Public Health Agency of Sweden (PHAS) evaluated these criteria for introducing varicella vaccination. Methods The
Annika Ersson, Kari Johansen, Sören Andersson   +2 more
wiley   +1 more source

Continued control of pneumococcal disease in the UK - the impact of vaccination

, 2011
Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-
Gladstone, R.A., Jefferies, J.M., Gladstone, R.A, S. N. Faust, Faust, S.N, Faust, S.N ., R. A. Gladstone, Clarke, S.C., J. M. Jefferies, Jefferies, J.M, Clarke, S.C, S. C. Clarke   +11 more
core   +1 more source

Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All

Vaccines, 2021
Despite the significant reduction in pneumococcal disease due to pneumococcal vaccines, protection of vulnerable high-risk individuals, especially pediatric populations, remains a great challenge.
Theano Lagousi, Ioanna Papadatou, Petros Strempas, Elena Chatzikalil, Vana Spoulou   +4 more
doaj   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine. [PDF]

, 2012
BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes.
Greenwood, Brian M, Godwin C. Enwere, Brown J Okoko, Nsekpong, Ekpedeme D, Godwin C Enwere, Ekpedeme D Nsekpong, Syed M. A. Zaman, Aderonke A. Odutola, Saaka, Mark, Zaman, Syed MA, Akinsola, Adebayo K, Richard A. Adegbola, Syed M A Zaman, Adebayo K. Akinsola, Aderonke A Odutola, Richard A Adegbola, Martin O. C. Ota, Okoko, Brown J, Odutola, Aderonke A, Martin O C Ota, Cutts, Felicity T, Felicity T Cutts, Ekpedeme D. Nsekpong, Felicity T. Cutts, Adebayo K Akinsola, Brown J. Okoko, Enwere, Godwin C, Brian M Greenwood, Mark Saaka, Adegbola, Richard A, Brian M. Greenwood, Ota, Martin OC   +31 more
core   +1 more source

Analysis of pneumococcal vaccination status and its influencing factors among young and middle-aged populations: an online survey

Zhongguo gonggong weisheng
ObjectiveTo understand the pneumococcal vaccination status and its influencing factors among young and middle-aged populations, and provide reference for promoting pneumococcal vaccination.
Ziying CHEN, Sijia ZHOU, Xin JIANG, Wen LIU, Yuhang MA, Kai WANG, Zhixiang DAI, Shuhan TANG, Chengxi ZHENG, Jianli HU, Zhihang PENG   +10 more
doaj   +1 more source